アブストラクト
| Title | パーキンソン病 ■Q1 パーキンソン病の症状に応じた薬剤調整の考え方は? ■Q2 新規抗パーキンソン病薬の位置づけ, 使い方は? |
|---|---|
| Subtitle | 特集 病棟・外来でよくみる気になる 神経診療Up to Date よくみる気になる神経症状・疾患へのアプローチ |
| Authors | 水間敦士 |
| Authors (kana) | |
| Organization | 東海大学医学部内科学系脳神経内科 |
| Journal | 月刊薬事 |
| Volume | 66 |
| Number | 4 |
| Page | 723-726 |
| Year/Month | 2024 / 3 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | 「Answer」早期パーキンソン病患者の運動症状には, レボドパ製剤やドパミンアゴニスト製剤, MAO-B阻害薬を使用するが, レボドパ製剤の1日投薬量は運動合併症の発現リスクにも考慮して処方する必要がある. また日常生活動作の最大限の改善を目指し, 持続的ドパミン刺激(continuous dopaminergic stimulation)を意識した処方が望ましく, ドパミンアゴニスト製剤(徐放剤, 貼付剤)が有用である. 進行期にみられる運動合併症に対しては早期からの処方内容に加えてレボドパ製剤の分割投与やCOMT阻害薬や非ドパミン製剤の併用を考慮する. 非運動症状に対してはMAO-B阻害薬追加も選択肢となる. 「早期における治療目標」早期パーキンソン病患者における治療指針として「パーキンソン病診療ガイドライン2018」では, 運動合併症(ジスキネジア, wearing-off)の発現リスクが高い若年発症者にはドパミンアゴニスト製剤やMAO-B阻害薬による治療開始が推奨される. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) 日本神経学会・編: パーキンソン病診療ガイドライン. 医学書院, 2018
- 2) PD Med Collaborative Group: Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease(PD MED): a large, open-label, pragmatic randomised trial. Lancet, 384: 1196-1205, 2014
- 3) Olanow CW, et al: Factors predictive of the development of Levodopa-induced. dyskinesia and wearing-off in Parkinson's disease. Mov Disord, 28: 1064-1071, 2013
- 4) Gungabissoon, et al: Comparison of long-term use of prolonged-release. ropinirole and immediate-release dopamine agonists in an observational study in patients with Parkinson's disease. Pharmacoepidemiol Drug Saf, 29: 591-598, 2020
- 5) Gray R, et al: Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial. JAMA Neurol, 79: 131-140, 2022
残りの12件を表示する
- 6) Tan YY, et al: Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future. J Parkinsons Dis, 12: 477-493, 2022
- 7) Ferreira JJ, et al: Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol, 15: 154-165, 2016
- 8) Giossi R, et al: Overall Efficacy and Safety of Safinamide in Parkinson's. Disease: A Systematic Review and a Meta-analysis. Clin Drug Investig, 41: 321-339, 2021
- 9) Hattori N, et al: The Effects of Safinamide Adjunct Therapy on Depression and. Apathy in Patients With Parkinson's Disease: Post-hoc Analysis of a Japanese Phase 2/3 Study. Front Neurol, 12: 752632, 2022
- 10) Garica DS, et al: Safinamide improves sleep and daytime sleepiness in. Parkinson's disease: results from the SAFINONMOTOR study. Neuro Sci, 43: 2537-2544, 2022
- 11) LeWitt P, et al: Opicapone Pharmacokinetics and Effects on Catechol- O -Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa. Clin Neuropharmacol, 46: 43-50, 2023
- 12) Ferreira JJ, et al: Effect of Opicapone on Levodopa Pharmacokinetics in. Patients with Fluctuating Parkinson's Disease. Mov Disord, 37: 2272-2283, 2022
- 13) Antonini A, et al: Developing consensus among movement disorder specialists. on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach. Curr Med Res Opin, 34: 2063-2073, 2018
- 14) Palhagen SE, et al: Levodopa-carbidopa intestinal gel(LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs. Parkinsonism Relat Disord, 29: 17-23, 2016
- 15) Rosebraugh M, et al: Foslevodopa/foscarbidopa subcutaneous infusion. maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum. Parkinsonism Relat Disord, 97: 68-72, 2022
- 16) Soileau MJ, et al: Safety and efficacy of continuous subcutaneous foslevodopa foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol, 21: 1099-1109, 2022
- 17) Fasano A, et al: Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: long-term results from COSMOS. J Neurol, 270: 2765-2775, 2023
